As of 2025-09-18, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -11.91 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.03 USD, the upside of Rocket Pharmaceuticals Inc is -493.04%.
Based on its market price of 3.03 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 493.04%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.91 - -11.91 | -11.91 | -493.04% |
| P/E | (6.62) - (26.30) | (16.49) | -644.4% |
| DDM - Stable | (29.28) - (557.75) | (293.51) | -9786.9% |
| DDM - Multi | (28.29) - (430.00) | (53.68) | -1871.5% |
| Market Cap (mil) | 326.94 |
| Beta | 1.66 |
| Outstanding shares (mil) | 107.90 |
| Enterprise Value (mil) | 315.12 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.04% |
| Cost of Debt | 5.00% |
| WACC | 6.84% |